First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.

Autor: Fricke J; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Westerbergh F; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden., McDougall L; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Favaretto C; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland., Christ E; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland.; Division of Endocrinology, University Hospital Basel, Basel, Switzerland., Nicolas GP; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland., Geistlich S; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland., Borgna F; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland., Fani M; Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland., Bernhardt P; Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.; Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden., van der Meulen NP; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland.; Laboratory of Radiochemistry, Paul Scherrer Institute (PSI), Villigen, Switzerland., Müller C; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Schibli R; Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Wild D; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland. damian.wild@usb.ch.; ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland. damian.wild@usb.ch.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Jul; Vol. 51 (8), pp. 2517-2519. Date of Electronic Publication: 2024 Mar 07.
DOI: 10.1007/s00259-024-06641-w
Databáze: MEDLINE